INVO Fertility, Inc. (IVF): debt financing — INVO Bioscience issues $150,000 in demand promissory notes to CEO and entity controlled by CFO

INVO Fertility, Inc.

$75,000 from CEO Steven Shum ($60,000 on Nov 29, $15,000 on Dec 2, 2022).
$75,000 from Andax LLC, an entity controlled by CFO Andrea Goren, on Nov 29, 2022.
Notes are interest-free if paid before Jan 31, 2023; otherwise 10% annual interest from issuance.
At maturity, principal plus a 10% financing fee and accrued interest are payable.
Notes callable with 10 days written notice starting 30 days from issuance.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

INVO Fertility, Inc. incurred loan of $150,000 with Steven Shum and entity controlled by Andrea Goren at 10% annual interest.

Instrument: loan
Principal: $150,000
Counterparty: Steven Shum and entity controlled by Andrea Goren
Rate: 10% annual interest
Event: incurrence

Exact text from the filing

From November 29, 2022 through December 2, 2022, INVO Bioscience, Inc. (the “Company”) received $150,000 through the issuance of demand promissory notes of which (1) $75,000 was received from our Chief Executive Officer, Steven Shum ($60,000 on November 29, 2022 and $15,000 on December 2, 2022) and (2) $75,000 was received from an entity controlled by our Chief Financial Officer, Andrea Goren (on November 29, 2022). If paid prior to January 31, 2023, the demand promissory notes are interest free until January 31, 2023. For any amount that remains outstanding past January 31, 2023, 10% annual interest would accrue from the date of issuance.

View on SEC.gov

90 debt financings filed in the last 30 days. Browse all debt financings →

INVO Fertility, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-034493

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.